Girard Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $1.49M | Sell |
8,710
-238
| -3% | -$39.4K | 0.14% | 114 |
|
|
2024
Q1 | $1.63M | Sell |
8,948
-404
| -4% | -$69.6K | 0.15% | 114 |
|
|
2023
Q4 | $1.45M | Buy |
9,352
+33
| +0.4% | +$4.81K | 0.15% | 124 |
|
|
2023
Q3 | $1.39M | Sell |
9,319
-383
| -4% | -$56.2K | 0.16% | 120 |
|
|
2023
Q2 | $1.31M | Sell |
9,702
-1,818
| -16% | -$267K | 0.14% | 124 |
|
|
2023
Q1 | $1.84M | Sell |
11,520
-922
| -7% | -$141K | 0.2% | 96 |
|
|
2022
Q4 | $2.01M | Buy |
12,442
+53
| +0.4% | +$8.13K | 0.23% | 100 |
|
|
2022
Q3 | $1.66M | Sell |
12,389
-9
| -0.1% | -$1.29K | 0.22% | 91 |
|
|
2022
Q2 | $1.9M | Sell |
12,398
-1,501
| -11% | -$229K | 0.24% | 93 |
|
|
2022
Q1 | $2.25M | Sell |
13,899
-6,608
| -32% | -$960K | 0.25% | 94 |
|
|
2021
Q4 | $2.78M | Buy |
20,507
+3,576
| +21% | +$422K | 0.3% | 89 |
|
|
2021
Q3 | $1.83M | Buy |
16,931
+5,896
| +53% | +$674K | 0.23% | 98 |
|
|
2021
Q2 | $1.24M | Buy |
11,035
+1,298
| +13% | +$146K | 0.16% | 112 |
|
|
2021
Q1 | $1.05M | Buy |
9,737
+950
| +11% | +$102K | 0.15% | 109 |
|
|
2020
Q4 | $941K | Sell |
8,787
-794
| -8% | -$76.3K | 0.14% | 109 |
|
|
2020
Q3 | $839K | Sell |
9,581
-907
| -9% | -$85.4K | 0.14% | 118 |
|
|
2020
Q2 | $1.03M | Sell |
10,488
-359
| -3% | -$31.6K | 0.19% | 107 |
|
|
2020
Q1 | $826K | Sell |
10,847
-394
| -4% | -$33.6K | 0.17% | 112 |
|
|
2019
Q4 | $995K | Buy |
11,241
+243
| +2% | +$20.2K | 0.16% | 115 |
|
|
2019
Q3 | $832K | Sell |
10,998
-1,107
| -9% | -$75.9K | 0.15% | 120 |
|
|
2019
Q2 | $880K | Sell |
12,105
-37
| -0.3% | -$2.91K | 0.16% | 118 |
|
|
2019
Q1 | $978K | Sell |
12,142
-764
| -6% | -$62.5K | 0.18% | 114 |
|
|
2018
Q4 | $1.19M | Sell |
12,906
-725
| -5% | -$63.8K | 0.25% | 94 |
|
|
2018
Q3 | $1.29M | Sell |
13,631
-627
| -4% | -$59.5K | 0.23% | 104 |
|
|
2018
Q2 | $1.32M | Buy |
+14,258
| New | +$1.39M | 0.25% | 101 |
|
|
2018
Q1 | – | Sell |
-13,990
| Closed | -$1.35M | – | 247 |
|
|
2017
Q4 | $1.35M | Buy |
13,990
+842
| +6% | +$79.4K | 0.26% | 99 |
|
|
2017
Q3 | $1.17M | Sell |
13,148
-517
| -4% | -$39.4K | 0.24% | 100 |
|
|
2017
Q2 | $991K | Sell |
13,665
-654
| -5% | -$44K | 0.21% | 109 |
|
|
2017
Q1 | $933K | Sell |
14,319
-1,220
| -8% | -$76.7K | 0.23% | 105 |
|
|
2016
Q4 | $973K | Buy |
15,539
+41
| +0.3% | +$2.5K | 0.28% | 97 |
|
|
2016
Q3 | $977K | Buy |
15,498
+2,181
| +16% | +$141K | 0.33% | 84 |
|
|
2016
Q2 | $824K | Sell |
13,317
-991
| -7% | -$60.4K | 0.31% | 85 |
|
|
2016
Q1 | $817K | Buy |
14,308
+1,022
| +8% | +$57K | 0.36% | 84 |
|
|
2015
Q4 | $787K | Buy |
13,286
+801
| +6% | +$46.1K | 0.38% | 80 |
|
|
2015
Q3 | $679K | Buy |
12,485
+915
| +8% | +$59.6K | 0.38% | 80 |
|
|
2015
Q2 | $777K | Sell |
11,570
-190
| -2% | -$12.4K | 0.43% | 74 |
|
|
2015
Q1 | $688K | Sell |
11,760
-3,167
| -21% | -$191K | 0.41% | 77 |
|
|
2014
Q4 | $977K | Sell |
14,927
-304
| -2% | -$19.2K | 0.61% | 56 |
|
|
2014
Q3 | $880K | Sell |
15,231
-620
| -4% | -$34.4K | 0.59% | 55 |
|
|
2014
Q2 | $895K | Sell |
15,851
-390
| -2% | -$20.5K | 0.62% | 54 |
|
|
2014
Q1 | $835K | Buy |
16,241
+1,471
| +10% | +$74.3K | 0.59% | 57 |
|
|
2013
Q4 | $780K | Buy |
+14,770
| New | +$726K | 0.62% | 52 |
|
Other funds holding ABBV
Girard Partners's ABBV Position: Q2 2024 in Review
Girard Partners reduced its AbbVie (ABBV) stake by 2.7% in Q2 2024, selling an estimated $39.4K and leaving 8,710 shares worth $1.49M. The position accounts for 0.14% of the portfolio, ranked #114.
Girard Partners first reported a position in ABBV in Q4 2013 and has held it in 42 quarters since. The position peaked at $2.78M in Q4 2021. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.
- Girard Partners held 8,710 shares of AbbVie worth $1.49M as of Q2 2024.
- Girard Partners sold 238 AbbVie shares in Q2 2024, an estimated $39.4K.
- AbbVie made up 0.14% of Girard Partners's portfolio in Q2 2024, its #114 holding.
- Girard Partners first reported a position in AbbVie in Q4 2013 and has held it in 42 quarters since.
- Girard Partners's AbbVie position peaked at $2.78M in Q4 2021.
- 3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.
Based on Girard Partners's 13F filing for Q2 2024, filed 12 Aug 2024.